SK Biopharmaceuticals makes Christopher Gallen CEO
This article was originally published in Scrip
South Korean pharmaceutical company SK Biopharmaceuticals has appointed Dr Christopher Gallen CEO. He will also serve as CEO of the wholly-owned American affiliate SK Life Science. Dr Gallen was most recently executive vie-president of Zalicus, where he led the clinical and commercial development of pain relief treatment Exalgo (hydromorphone). He previously served at Wyeth Research as vice-president and chief of operations, clinical research and development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.